Evidence map›Paper›PMID 23055136›Full record

ArticleInternational journal of cancer2013

Multifunctional nanobeacon for imaging Thomsen-Friedenreich antigen-associated colorectal cancer.

Hironori Kumagai, Wellington Pham, Makoto Kataoka, Ken-Ichiro Hiwatari, James McBride, Kevin J Wilson, Hiroyuki Tachikawa, Ryoji Kimura, Kunio Nakamura, Eric H Liu and 2 more

Open access · bronzeAbstract readComparative Study
In one paragraph

Article in International journal of cancer, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
2.0field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 20 citations in OpenAlex.

  1. Article
  2. Review
  3. Tumor recognition of peanut agglutinin-immobilized fluorescent nanospheres in biopsied human tissues.European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V · 2019
    Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 2 countries.

Hironori KumagaiInstitute of Imaging Science, Vanderbilt University, Nashville, TN 37232, USA.
Wellington Pham
Makoto Kataoka
Ken-Ichiro Hiwatari
James McBride
Kevin J Wilson
Hiroyuki Tachikawa
Ryoji Kimura
Kunio Nakamura
Eric H Liu
John C Gore
Shinji Sakuma
Vanderbilt University · USSetsunan University · JP

Funding

Vanderbilt In Vivo Cellular and Molecular Imaging CenterP50CA128323 · NCI · VANDERBILT UNIVERSITY · PI SHYR, YU · 2008 to 2012
$6.8M
Multifunctional Nanoparticles for Image-Guided Vaccine Delivery in CancerR01CA160700 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI PHAM, WELLINGTON · 2012 to 2015
$1.3M
NCI NIH HHS P50 CA128323NCI NIH HHS P50CA128323NCI NIH HHS R01 CA160700NCI NIH HHS R01CA160700
6 · The paper itself

Abstract

This research aimed to validate the specificity of the newly developed nanobeacon for imaging the Thomsen-Friedenreich (TF) antigen, a potential biomarker of colorectal cancer. The imaging agent is comprised of a submicron-sized polystyrene nanosphere encapsulated with a Coumarin 6 dye. The surface of the nanosphere was modified with peanut agglutinin (PNA) and poly(N-vinylacetamide (PNVA) moieties. The former binds to Gal-β(1-3)GalNAc with high affinity while the latter enhances the specificity of PNA for the carbohydrates. The specificity of the nanobeacon was evaluated in human colorectal cancer cells and specimens, and the data were compared with immunohistochemical staining and flow cytometric analysis. Additionally, distribution of the nanobeacon in vivo was assessed using an "intestinal loop" mouse model. Quantitative analysis of the data indicated that approximately 2 μg of PNA were detected for each milligram of the nanobeacon. The nanobeacon specifically reported colorectal tumors by recognizing the tumor-specific antigen through the surface-immobilized PNA. Removal of TF from human colorectal cancer cells and tissues resulted in a loss of fluorescence signal, which suggests the specificity of the probe. Most importantly, the probe was not absorbed systematically in the large intestine upon topical application. As a result, no registered toxicity was associated with the probe. These data demonstrate the potential use of this novel nanobeacon for imaging the TF antigen as a biomarker for the early detection and prediction of the progression of colorectal cancer at the molecular level.

Indexed as

CoumarinsNanospheresPeanut AgglutininThiazolesAnimalsAntigens, Tumor-Associated, CarbohydrateBlotting, WesternCase-Control StudiesColonColorectal NeoplasmsDiagnostic ImagingFluorescent DyesHumansImmunoenzyme TechniquesMaleMiceAntigens, Tumor-Associated, Carbohydratecoumarin 6CoumarinsFluorescent DyesPeanut AgglutininPolystyrenesRNA, MessengerThiazolesThomsen-Friedenreich antigen

Identifiers

PMID23055136
PMCPMC3566327
OpenAlexW2095019664

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.